文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

主动协议化药物治疗管理预防急诊普通病房谵妄:单中心随机对照试验方案

Preventive effects of active Protocol-Based Pharmacotherapy Management for delirium in general wards of emergency department (aPBPM trial): study protocol for a single-center, randomized controlled trial {1a}.
PubMed 文献 · Trials · 2026-05-20

本研究为单中心、开放标签、随机对照试验,拟纳入年龄≥65岁且至少有一个谵妄危险因素的急诊普通病房患者,1:1随机分为主动协议化药物治疗管理(PBPM)组与被动PBPM组。主动组自入院第1天起由药师干预给予预防性药物3天,被动组仅在出现失眠时干预。主要结局为前3天内由精神科医生依据DSM-5诊断的谵妄发生率。

要点

  • 主动PBPM组药师主导预防性用药3天,被动组仅失眠时干预。
  • 主要结局为前3天精神科医生依据DSM-5诊断的谵妄发生率。
  • 次要结局包括谵妄严重程度(DRS-R-98)与安全性。

核心结论

  • 该试验旨在评估主动PBPM策略相比被动PBPM策略在老年急诊患者中预防谵妄的疗效与安全性。

研究设计与样本

  • 单中心、开放标签、随机对照试验,纳入年龄≥65岁且至少有一个危险因素的急诊普通病房患者,1:1随机分组。

关键数值与推荐

  • 主动PBPM组自入院第1天起由药师干预给予预防性药物3天。
  • 能口服者睡前接受雷美替胺8 mg与莱博雷生5 mg。
  • 不能口服者接受布南色林贴剂20 mg,于19:00-06:00过夜贴敷。
  • 被动PBPM组仅在出现失眠时进行药物干预。
  • 主要结局为前3天内由精神科医生依据DSM-5诊断的谵妄发生率。

临床怎么用

  • 若证实有效,药师主导的主动预防性用药可能成为急诊老年高危患者谵妄预防的新标准。

局限性

  • 单中心、开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delirium is a frequent complication in older patients admitted to emergency wards, leading to prolonged hospitalization and increased mortality. Although multicomponent interventions are recommended, the evidence for pharmacological prevention remains inconsistent. Protocol-Based Pharmacotherapy Management (PBPM) allows pharmacists to actively manage medications according to a pre-agreed protocol. This study aims to evaluate the efficacy and safety of an "Active PBPM" strategy for delirium prevention compared with that via a standard "Passive PBPM" strategy in elderly emergency patients. METHODS: This single-center, open-label, randomized controlled trial will target patients aged ≥65 years admitted to the general ward of the Department of Primary Care and Emergency Medicine from the emergency room. Eligible patients must have at least one risk factor (e.g., cognitive dysfunction, central nervous system disease). The patients will be randomized (1:1) into either the Active or Passive PBPM group. In the Active PBPM group, pharmacists will intervene to administer prophylactic medication for 3 days, starting on admission day 1. Patients capable of oral intake will receive ramelteon (8 mg) and lemborexant (5 mg) at bedtime. Patients unable to take oral medication will receive a blonanserin patch (20 mg) applied overnight (19:00-06:00). In the Passive PBPM group, pharmacological intervention will be performed only if insomnia occurs. The primary outcome will be the incidence of delirium diagnosed by a psychiatrist based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria, within the first 3 days. The secondary outcomes include delirium severity (Delirium Rating Scale-Revised-98), assessed by trained nurses, and safety. DISCUSSION: This study will determine whether pharmacist-led proactive pharmacological intervention (Active PBPM) reduces the incidence of delirium in high-risk older patients in acute care settings. The findings may establish a new standard of care for the prevention of delirium in emergency medicine. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) jRCTs051220122. Registered on November 25, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Takatani Y, Sato Y, Sugita N, et al. Preventive effects of active Protocol-Based Pharmacotherapy Management for delirium in general wards of emergency department (aPBPM trial): study protocol for a single-center, randomized controlled trial {1a}. Trials. 2026. PMID: 42163281. doi:10.1186/s13063-026-09781-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。